Epcoritamab
- Generic Name
- Epcoritamab
- Brand Names
- Epkinly, Tepkinly
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2134641-34-0
- Unique Ingredient Identifier
- D6OMY2L0WA
- Background
Epcoritamab is an IgG1-bispecific antibody that simultaneously binds to CD3 on T-cells and CD20 on B-cells. Epcoritamab promotes the activation and expansion of T-cells and, by being able to bind to both CD20 and CD3, it leads to the T-cellโmediated killing of CD20+ malignant B cells. Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of cancer comm...
- Indication
Epcoritamab is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under acc...
- Associated Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
- Associated Therapies
- -
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 40
- Registration Number
- NCT06414148
- Locations
- ๐ฆ๐บ
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
๐ฆ๐บRoyal Prince Alfred Hospital, Camperdown, New South Wales, Australia
๐ฆ๐บRoyal Brisbane and Women's Hospital, Herston, Queensland, Australia
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
- Conditions
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Australasian Leukaemia and Lymphoma Group
- Target Recruit Count
- 39
- Registration Number
- NCT06287398
- Locations
- ๐ฆ๐บ
Australasian Leukemia and Lymphoma Group, Melbourne, Victoria, Australia
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 120
- Registration Number
- NCT06238648
- Locations
- ๐บ๐ธ
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
๐บ๐ธHackensack University Medical Center, Hackensack, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 1080
- Registration Number
- NCT06191744
- Locations
- ๐บ๐ธ
Rocky Mountain Cancer Centers - Boulder /ID# 261203, Boulder, Colorado, United States
๐บ๐ธChristiana Care Health Service /ID# 261207, Newark, Delaware, United States
๐บ๐ธOncology Hematology Care, Inc - Blue Ash /ID# 261204, Cincinnati, Ohio, United States
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06045247
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Dipenkumar Modi
- Target Recruit Count
- 32
- Registration Number
- NCT05852717
- Locations
- ๐บ๐ธ
University of Virginia Health System, Charlottesville, Virginia, United States
๐บ๐ธIndiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธKarmanos Cancer Center (Wayne State University), Detroit, Michigan, United States
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
- Conditions
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 284
- Registration Number
- NCT05848765
- Locations
- ๐ฌ๐ง
Cardiff and vale University LHB, Cardiff, United Kingdom
๐ฌ๐งBelfast Health & Social Care Trust, Belfast, United Kingdom
๐ฌ๐งNHS Grampian, Aberdeen, United Kingdom
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2024-04-12
- Target Recruit Count
- 112
- Registration Number
- NCT05791409
- Locations
- ๐ณ๐ฑ
NL-Tilburg-ETZ, Tilburg, Netherlands
๐ณ๐ฑNL-Alkmaar-NWZ, Alkmaar, Netherlands
๐ฉ๐ชDE-Freiburg-UNIKLINIKFREIBURG, Freiburg, Germany
Epcoritamab and Rituximab for First-line Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Reid Merryman, MD
- Target Recruit Count
- 35
- Registration Number
- NCT05783609
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธThe Ohio State University Wexner Medical Center, Columbus, Ohio, United States
๐บ๐ธUniversity of Rochester Medical Center, Rochester, New York, United States
Expanded Access to Epcoritamab
- Conditions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- AbbVie
- Registration Number
- NCT05692050
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.